ArQule Company Profile (NASDAQ:ARQL)

About ArQule (NASDAQ:ARQL)

ArQule logoArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARQL
  • CUSIP: 04269E10
  • Web:
  • Market Cap: $87.51 million
  • Outstanding Shares: 71,146,000
Average Prices:
  • 50 Day Moving Avg: $1.02
  • 200 Day Moving Avg: $1.25
  • 52 Week Range: $0.92 - $2.17
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.00
  • P/E Growth: -0.46
Sales & Book Value:
  • Annual Revenue: $3.48 million
  • Price / Sales: 25.15
  • Book Value: $0.24 per share
  • Price / Book: 5.13
  • EBIDTA: ($25,050,000.00)
  • Net Margins: -296.69%
  • Return on Equity: -55.62%
  • Return on Assets: -43.73%
  • Current Ratio: 4.51%
  • Quick Ratio: 4.51%
  • Average Volume: 172,718 shs.
  • Beta: 1.51
  • Short Ratio: 2.07

Frequently Asked Questions for ArQule (NASDAQ:ARQL)

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) announced its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.00. ArQule had a negative net margin of 296.69% and a negative return on equity of 55.62%. During the same quarter last year, the business earned ($0.08) earnings per share. View ArQule's Earnings History.

When will ArQule make its next earnings announcement?

ArQule is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for ArQule.

Are investors shorting ArQule?

ArQule saw a increase in short interest in April. As of April 28th, there was short interest totalling 742,424 shares, an increase of 2.1% from the April 13th total of 727,505 shares. Based on an average daily trading volume, of 53,356 shares, the days-to-cover ratio is currently 13.9 days.

Who are some of ArQule's key competitors?

Who owns ArQule stock?

ArQule's stock is owned by a number of of retail and institutional investors. Top institutional investors include First Eagle Investment Management LLC (15.34%), Vanguard Group Inc. (0.00%), NEA Management Company LLC (0.00%), Renaissance Technologies LLC (0.00%), FMR LLC (0.00%) and Geode Capital Management LLC (0.00%). Company insiders that own ArQule stock include Michael D Loberg, Paolo Pucci and Patrick J Zenner. View Institutional Ownership Trends for ArQule.

Who sold ArQule stock? Who is selling ArQule stock?

ArQule's stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, FMR LLC, State of New Jersey Common Pension Fund D, Stoneridge Investment Partners LLC and Renaissance Technologies LLC. View Insider Buying and Selling for ArQule.

Who bought ArQule stock? Who is buying ArQule stock?

ArQule's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought ArQule stock in the last two years include Michael D Loberg, Paolo Pucci and Patrick J Zenner. View Insider Buying and Selling for ArQule.

How do I buy ArQule stock?

Shares of ArQule can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ArQule stock cost?

One share of ArQule stock can currently be purchased for approximately $1.23.

Analyst Ratings

Consensus Ratings for ArQule (NASDAQ:ARQL) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for ArQule (NASDAQ:ARQL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/1/2016Leerink SwannLower Price TargetMarket Perform$3.00 -> $2.50N/AView Rating Details
12/27/2015Royal Bank of CanadaUpgradeBuyN/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for ArQule (NASDAQ:ARQL)
Earnings by Quarter for ArQule (NASDAQ:ARQL)
Earnings History by Quarter for ArQule (NASDAQ:ARQL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($0.11)($0.11)ViewListenView Earnings Details
3/7/2017Q4 2016($0.10)($0.10)$1.20 million$1.19 millionViewListenView Earnings Details
11/7/2016Q316($0.09)($0.08)$1.10 million$1.22 millionViewListenView Earnings Details
8/3/2016Q216($0.08)($0.07)$1.13 million$1.07 millionViewN/AView Earnings Details
5/4/2016Q116($0.07)($0.08)$1.63 million$1.28 millionViewN/AView Earnings Details
2/29/2016Q415($0.06)($0.05)$2.40 million$2.80 millionViewListenView Earnings Details
11/4/2015Q315($0.08)($0.04)$2.60 million$2.65 millionViewN/AView Earnings Details
8/5/2015Q215($0.08)($0.06)$2.50 million$3.04 millionViewN/AView Earnings Details
5/6/2015Q115($0.08)($0.07)$1.98 million$2.79 millionViewN/AView Earnings Details
3/4/2015Q414($0.13)($0.06)$1.90 million$3.02 millionViewN/AView Earnings Details
11/10/2014Q314($0.13)($0.10)$2.20 million$2.66 millionViewN/AView Earnings Details
8/5/2014Q214($0.13)($0.10)$2.43 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.11)($0.11)$2.29 million$2.67 millionViewN/AView Earnings Details
3/5/2014Q413($0.13)($0.10)$2.27 million$2.28 millionViewN/AView Earnings Details
10/31/2013Q313($0.13)($0.10)$2.77 million$3.50 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.12)($0.11)$3.84 million$4.44 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.11)($0.09)$3.78 million$5.66 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.13)($0.09)$5.17 million$5.14 millionViewN/AView Earnings Details
11/1/2012($0.07)($0.01)ViewN/AView Earnings Details
8/2/2012($0.07)($0.01)ViewN/AView Earnings Details
5/3/2012($0.07)($0.08)ViewN/AView Earnings Details
3/1/2012($0.09)$0.07ViewN/AView Earnings Details
11/10/2011($0.23)($0.04)ViewN/AView Earnings Details
8/4/2011($0.19)($0.20)ViewN/AView Earnings Details
5/5/2011($0.08)($0.03)ViewN/AView Earnings Details
3/1/2011($0.15)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ArQule (NASDAQ:ARQL)
2017 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)


Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ArQule (NASDAQ:ARQL)
Insider Ownership Percentage: 8.30%
Institutional Ownership Percentage: 58.99%
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)
Institutional Ownership by Quarter for ArQule (NASDAQ:ARQL)
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2015Michael D LobergDirectorBuy3,719$2.16$8,033.04View SEC Filing  
12/16/2015Michael D LobergDirectorBuy1,231$2.14$2,634.34View SEC Filing  
12/15/2015Paolo PucciCEOBuy1,283$2.16$2,771.28View SEC Filing  
12/11/2015Paolo PucciCEOBuy1,108$2.10$2,326.80View SEC Filing  
12/11/2015Patrick J ZennerDirectorBuy2,300$2.15$4,945.00View SEC Filing  
12/10/2015Paolo PucciCEOBuy7,609$2.10$15,978.90View SEC Filing  
3/11/2015Patrick J ZennerDirectorBuy10,625$2.32$24,650.00View SEC Filing  
11/20/2014Paolo PucciCEOBuy5,000$1.26$6,300.00View SEC Filing  
11/14/2014Patrick J ZennerDirectorBuy20,830$1.20$24,996.00View SEC Filing  
11/13/2014Susan L KelleyDirectorBuy50,000$1.20$60,000.00View SEC Filing  
9/4/2014Paolo PucciCEOBuy5,000$1.31$6,550.00View SEC Filing  
5/23/2014Paolo PucciCEOBuy5,000$1.40$7,000.00View SEC Filing  
5/20/2014Paolo PucciCEOBuy5,000$1.42$7,100.00View SEC Filing  
3/17/2014Patrick ZennerDirectorBuy4,715$2.12$9,995.80View SEC Filing  
3/13/2014Paolo PucciCEOBuy10,000$2.10$21,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ArQule (NASDAQ:ARQL)
Latest Headlines for ArQule (NASDAQ:ARQL)
DateHeadline logoArQule Stock Up 28% on Lab Data for B-Cell Lymphoma Drug - May 19 at 9:27 AM logoArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA) - May 18 at 12:06 PM logoArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - May 17 at 8:40 PM logoArQule, Inc. (ARQL) Short Interest Update - May 15 at 8:48 AM logo-$0.11 EPS Expected for ArQule, Inc. (ARQL) This Quarter - May 9 at 6:16 PM logoLeerink Swann Brokers Cut Earnings Estimates for ArQule, Inc. (ARQL) - May 8 at 8:26 AM logoArQule, Inc. (ARQL) Downgraded to "Sell" at Zacks Investment Research - May 4 at 7:06 PM logoEdited Transcript of ARQL earnings conference call or presentation 3-May-17 1:00pm GMT - May 4 at 1:47 AM logoArQule, Inc. (ARQL) Issues Earnings Results, Meets Expectations - May 3 at 12:33 PM logoArqule Reports First Quarter 2017 Financial Results - May 3 at 9:55 AM logoArQule reports 1Q loss - May 3 at 9:55 AM logoInvestor Network: ArQule, Inc. to Host Earnings Call - May 3 at 9:55 AM logoArQule (ARQL) Earns Daily Media Impact Rating of 0.13 - May 2 at 8:16 AM logoArQule, Inc. (ARQL) Scheduled to Post Earnings on Wednesday - May 1 at 11:56 AM logoArQule (ARQL) Receiving Somewhat Favorable News Coverage, Report Shows - April 27 at 4:38 PM logoArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531 - April 26 at 9:10 AM logoArQule (ARQL) Earning Somewhat Positive Press Coverage, Report Finds - April 20 at 2:42 PM logoArQule To Report First Quarter 2017 Financial Results On May 3, 2017 - April 19 at 9:15 AM logo-$0.10 EPS Expected for ArQule, Inc. (ARQL) This Quarter - April 18 at 10:21 PM logoSomewhat Favorable Media Coverage Somewhat Likely to Impact ArQule (ARQL) Stock Price - April 17 at 12:07 PM logoSomewhat Critical Press Coverage Somewhat Likely to Effect ArQule (ARQL) Share Price - April 14 at 7:58 AM logoArQule (ARQL) Announces IND Application for BTK Inhibitor ARQ 531 Cleared by FDA - - April 11 at 8:03 AM logoArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531 - April 11 at 8:03 AM logoETFs with exposure to ArQule, Inc. : April 5, 2017 - April 7 at 8:07 AM logoFDA Nod For TSRO, Déjà Vu For ARQL, FOMX Plunges On Trial Data, SELB Abuzz - RTT News - March 28 at 3:38 PM logoArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017 - March 28 at 10:32 AM logoPre-Open Movers 03/27: (HTGM) (WFT) (SNAP) Higher; (FOMX) (ARQL) (MEET) Lower (more...) - March 27 at 3:42 PM logoArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan - March 27 at 8:30 AM logoZacks: ArQule, Inc. (ARQL) Given $1.30 Consensus Price Target by Analysts - March 23 at 10:43 AM logoARQULE INC Financials - March 15 at 3:54 PM logoARQULE INC Files SEC form 10-K, Annual Report - March 9 at 9:15 PM logoEdited Transcript of ARQL earnings conference call or presentation 7-Mar-17 2:00pm GMT - March 8 at 1:41 AM logoEARNINGS SUMMARY: Details of ArQule Inc. Q4 Earnings Report - March 7 at 3:40 PM logoArQule's (ARQL) CEO Paolo Pucci on Q4 2016 Results - Earnings Call Transcript - March 7 at 3:40 PM logoArQule Reports Fourth Quarter and Full Year 2016 Financial Results - March 7 at 3:40 PM logoQ4 2016 ArQule Inc Earnings Release - Before Market Open - March 7 at 3:40 PM logoARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 7 at 8:28 AM logoArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017 - February 24 at 12:37 PM logoArQule Liver Cancer Drug Fails Phase 3 (ARQL) - February 20 at 3:32 PM logoArQule Liver Cancer Drug Fails Phase 3 Trial - February 20 at 3:32 PM logoArQule (ARQL), Daiichi Sankyo Phase 3 Study of Tivantinib Misses ... - - February 18 at 3:35 PM logoArQule (ARQL), Daiichi Sankyo Phase 3 Study of Tivantinib Misses Primary Endpoint - February 18 at 9:50 AM logoArQule, Inc. (ARQL) - February 18 at 9:50 AM logoDaiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma - February 18 at 9:50 AM logo6:02 am ArQule and Daiichi Sankyo (DSNKY) announce the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma did not meet its primary endpoint of improving overall survival - February 18 at 9:50 AM logoARQULE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits - February 18 at 9:50 AM logoBUZZ-U.S. STOCKS ON THE MOVE-Banks, Kraft, Mondelez ... - Nasdaq - February 17 at 6:24 PM logoArQule to Present at The Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017 - February 8 at 3:51 PM logoArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher - February 2 at 3:39 PM



ArQule (ARQL) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff